Insider Selling: Pharvaris (NASDAQ:PHVS) CEO Sells 2,292 Shares

Pharvaris N.V. (NASDAQ:PHVS) CEO Berndt Modig sold 2,292 shares of the firm’s stock in a transaction on Friday, August 14th. The shares were sold at an average price of $34.77, for a total transaction of $79,692.84. Following the sale, the chief executive officer owned 130,625 shares in the company, valued at $4,541,831.25. The trade was a 1.72% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this hyperlink.

Berndt Modig also recently made the following trade(s):

• On Monday, June 15th, Berndt Modig sold 2,291 shares of Pharvaris stock. The shares were sold at an average price of $31.07, for a total value of $71,181.37.

Pharvaris Stock Up 0.5%

PHVS stock traded up $0.17 during midday trading on Tuesday, hitting $35.48. The company’s stock had a trading volume of 249,398 shares, compared to its average volume of 317,631. Pharvaris N.V. has a 12 month low of $20.65 and a 12 month high of $36.93. The firm has a market capitalization of $2.32 billion, a price-to-earnings ratio of -11.62 and a beta of -2.31. The company has a 50 day moving average of $33.79 and a two-hundred day moving average of $30.17.

Pharvaris (NASDAQ:PHVS) last released its quarterly earnings data on Wednesday, August 12th. The company reported ($0.81) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.75) by ($0.06). On average, analysts anticipate that Pharvaris N.V. will post -3.08 earnings per share for the current fiscal year.

Hedge Funds Weigh In On Pharvaris

A number of institutional investors and hedge funds have recently added to or reduced their stakes in the business. California State Teachers Retirement System grew its position in shares of Pharvaris by 2.2% in the fourth quarter. California State Teachers Retirement System now owns 23,982 shares of the company’s stock valued at $666,000 after purchasing an additional 520 shares during the last quarter. JPMorgan Chase & Co. increased its holdings in Pharvaris by 30.6% in the 2nd quarter. JPMorgan Chase & Co. now owns 3,342 shares of the company’s stock worth $59,000 after buying an additional 783 shares in the last quarter. Quantbot Technologies LP purchased a new position in Pharvaris in the 2nd quarter worth about $41,000. GF Fund Management CO. LTD. bought a new position in Pharvaris during the 4th quarter valued at about $35,000. Finally, Public Employees Retirement System of Ohio boosted its holdings in shares of Pharvaris by 20.7% during the 4th quarter. Public Employees Retirement System of Ohio now owns 7,569 shares of the company’s stock valued at $210,000 after acquiring an additional 1,300 shares during the last quarter.

Wall Street Analyst Weigh In

Several equities research analysts have recently weighed in on the stock. Royal Bank Of Canada increased their price objective on shares of Pharvaris from $51.00 to $52.00 and gave the stock an “outperform” rating in a research report on Thursday, August 13th. HSBC raised shares of Pharvaris to an “overweight” rating in a research note on Thursday, August 13th. New Street Research set a $60.00 price objective on shares of Pharvaris in a research note on Friday. UBS Group set a $74.00 price objective on shares of Pharvaris in a report on Wednesday, May 13th. Finally, Wells Fargo & Company initiated coverage on shares of Pharvaris in a research report on Wednesday, July 15th. They set an “overweight” rating and a $55.00 target price for the company. One analyst has rated the stock with a Strong Buy rating, eleven have issued a Buy rating, one has issued a Hold rating and one has assigned a Sell rating to the company’s stock. According to MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and an average price target of $51.08.

Key Headlines Impacting Pharvaris

Here are the key news stories impacting Pharvaris this week:

• Positive Sentiment: HC Wainwright maintained a Buy rating on Pharvaris, signaling continued confidence in the company’s long-term opportunity. The analyst still forecasts a shift to profitability by FY2029, with projected earnings of $3.09 per share. HC Wainwright Predicts Pharvaris’ Q4 Earnings
• Neutral Sentiment: HC Wainwright issued quarterly estimates of losses per share of $0.92 for Q3 2026, $0.98 for Q4 2026, $0.99 for Q1 2027, $0.89 for Q2 2027 and $0.77 for Q3 2027. The firm projects a FY2026 loss of $3.41 per share and a FY2027 loss of $3.30 per share, indicating that Pharvaris is expected to remain unprofitable in the near term.
• Negative Sentiment: The analyst lowered its FY2026 loss estimate from $2.98 to $3.41 per share and cut its FY2027 loss estimate from $2.41 to $3.30. Longer-term forecasts also weakened: FY2028 estimates moved from a $0.02 loss to a $0.56 loss, while FY2029 earnings were reduced from $3.23 to $3.09 per share. These revisions suggest higher anticipated expenses or a slower path to profitability and could limit upside despite the continued Buy rating.

Pharvaris Company Profile

Pharvaris is a clinical-stage biopharmaceutical company focused on discovering and developing novel oral therapies for rare bradykinin-driven diseases. The company’s core mission is to address conditions characterized by uncontrolled activation of the plasma kallikrein-kinin system, with a primary emphasis on hereditary angioedema (HAE), a debilitating disorder marked by recurrent swelling episodes.

The company’s lead program, PHA121, is an investigational once-daily oral plasma kallikrein inhibitor designed for prophylactic treatment of HAE and is advancing through clinical trials.